Mesoblast Ltd has released a press release.
Preliminary Final Report including Appendix 4E
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallIn the deck
Story so far
Earlier from Mesoblast
- Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
- Mesoblast Financial Results and Corporate Update Webcast
- Successful Commercial Launch of Ryoncil®
- Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
- Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
Later from Mesoblast
- Annual Financial Results Presentation
- MSB Annual Financial Results and Operational Update
- Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
- Mesoblast Option to Issue up to US$50m Convertible Notes
- Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast